Exelixis - EXEL Stock Forecast, Price & News

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" EXEL shares.
View EXEL analyst ratings or view top-rated stocks.

9 Wall Street analysts have issued twelve-month price targets for Exelixis' shares. Their EXEL share price forecasts range from $20.00 to $32.00. On average, they anticipate the company's share price to reach $26.00 in the next twelve months. This suggests a possible upside of 39.3% from the stock's current price.
View analysts price targets for EXEL or view top-rated stocks among Wall Street analysts.

Exelixis' stock was trading at $16.04 at the start of the year. Since then, EXEL shares have increased by 16.3% and is now trading at $18.66.
View the best growth stocks for 2023 here.

Exelixis saw a decline in short interest in March. As of March 15th, there was short interest totaling 8,040,000 shares, a decline of 11.6% from the February 28th total of 9,090,000 shares. Based on an average daily volume of 3,120,000 shares, the days-to-cover ratio is presently 2.6 days.
View Exelixis' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our EXEL earnings forecast.

Exelixis, Inc. (NASDAQ:EXEL) released its earnings results on Tuesday, February, 7th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by $0.04. The biotechnology company had revenue of $423.92 million for the quarter, compared to analyst estimates of $418.71 million. Exelixis had a trailing twelve-month return on equity of 7.54% and a net margin of 11.31%. The business's revenue was down 6.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.29 earnings per share.

ETFs with the largest weight of Exelixis (NASDAQ:EXEL) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), First Trust NYSE Arca Biotechnology Index Fund (FBT), Invesco Dynamic Biotechnology & Genome ETF (PBE), Virtus LifeSci Biotech Products ETF (BBP), First Trust Health Care AlphaDEX Fund (FXH), Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD), IQ U.S. Mid Cap R&D Leaders ETF (MRND) and SPDR S&P Biotech ETF (XBI).

Exelixis issued an update on its fourth quarter 2022 earnings guidance on Monday, January, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $415.00 million-$415.00 million, compared to the consensus revenue estimate of $414.83 million.

75 employees have rated Exelixis Chief Executive Officer Michael M. Morrissey on Glassdoor.com. Michael M. Morrissey has an approval rating of 79% among the company's employees. 38.0% of employees surveyed would recommend working at Exelixis to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Exelixis investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Intel (INTC), Alibaba Group (BABA), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Vertex Pharmaceuticals (VRTX) and AbbVie (ABBV).

Exelixis trades on the NASDAQ under the ticker symbol "EXEL."

Exelixis' stock is owned by many different institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (4.62%), Price T Rowe Associates Inc. MD (2.05%), Meditor Group Ltd (2.05%), Point72 Asset Management L.P. (1.98%), Geode Capital Management LLC (1.41%) and Dimensional Fund Advisors LP (1.36%). Insiders that own company stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, Dana Aftab, George A Scangos, George Poste, Gisela Schwab, Jack L Wyszomierski, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Patrick J Haley, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi.
View institutional ownership trends.

Shares of EXEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EXEL stock can currently be purchased for approximately $18.66.

Exelixis (NASDAQ:EXEL) has a market capitalization of $6.05 billion and generates $1.61 billion in revenue each year. The biotechnology company earns $182.28 million in net income (profit) each year or $0.57 on an earnings per share basis.

The company employs 1,223 workers across the globe.

Exelixis' mailing address is 1851 Harbor Bay Parkway, Alameda CA, 94502. The official website for the company is www.exelixis.com. The biotechnology company can be reached via phone at (650) 837-7000, via email at shubbard@exelixis.com, or via fax at 650-837-8300.